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1. Introduction 
1.1 Acute leukemias 
Acute leukemias are a heterogeneous group of malignancies that result from the malignant 
transformation of immature hematopoietic cells followed by clonal proliferation and 
accumulation of the transformed cells. They are characterized by aberrant differentiation 
and maturation of the malignant cells, with a maturation arrest and accumulation of more 
than 20% of leukemic blast in the bone marrow (Lichtman et al., 2010).  
The natural history of acute leukemia and the response to therapy varies according to the 
type of blast involved in the leukemic process. Although in many instances the lineage 
assignment of the different types of blast cells may be recognized by simple morphological 
and cytochemical stains, it is necessary to employ immunological analyses with monoclonal 
antibodies and cytogenetic or molecular biological techniques to identify their particular 
differentiation features (Haferlach et al., 2007).  
Acute leukemias are primarily characterized according to their differentiation along the 
myeloid and lymphoid lineage and they are divided into two main groups: acute myeloid 
leukemia (AML) and acute lymphoblastic leukemia (ALL). In 10% to 20% of patients, the 
leukemic cells have characteristics of both myeloid and lymphoid cells (Lichtman et 
al.,2010).  
The classification of the acute leukemias underwent many changes in recent years. The French-
American-British (FAB) classification of AML and ALL was based on cytomorphological and 
cytohemistry details only. Since then, the diagnostic of acute leukemias had undergone a 
complete change and the routine diagnostic work-up incorporated immunophenotyping by 
multiparameter flow cytometry, classical cytogenetics, molecular cytogenetics (comprising 
diverse fluorescence in situ hybridization techniques and comparative genomic hybridization) 
and molecular genetics (mostly polymerase chain reaction (PCR)-based techniques and 
sequencing) (Bennet et al., 1997; First MIC Cooperative Study Group, 1985; Haferlach et al., 
2007).  
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According to the proceedings in diagnostic methods and the improved understanding of the 
diversity of acute leukemia subtypes, the latest World Health Organization (WHO) 
classification of acute leukemias incorporates and interrelates morphology, cytogenetics, 
molecular genetics and immunologic markers and pays major attention on the importance 
of genetic events in the classification, prognosis and therapy of the AMLs. Its prognostic 
relevance is most clearly demonstrated in the AMLs characterized by recurrent chromosome 
translocation: t(15,17), t(8,21) and inv(16)/t(16,16) which generally have a favorable 
prognosis when treated with appropriate therapeutic agents. All other genetic events 
identified among AMLs had strong prognostic meaning but did not influence on the 
therapeutic decision (Swerdlow et al., 2008).  
In the WHO classification of precursor B-cell and T-cell neoplasms, immunophenotying of 
the malignant cells plays a decisive role in the diagnosis, prognosis and clinical stratification 
of patients (Swerdlow et al., 2008). 
Correct diagnosis of the diverse subtypes of AML and ALL play a central role for individual 
clinical risk stratification and therapeutic decisions.  
1.2 Acute myeloid leukemia 
Acute myeloid leukemia (AML) is one of the most common types of leukemia in adults. It is 
characterized by limited myeloid differentiation of the malignant cells. The malignant cells 
characteristically undergo maturation arrest at the level of the early myloblast or 
promyelocyte, although varying proportions of mature hematopoietic cells are leukemia 
derived. The cells that display myeloid markers include morphology, Auer rods (aberrant 
primary granules), cytochemistry (Sudan black, myeloperoxidase, or nonspecific esterase), 
and cell surface antigens (Lichtman et al., 2010). 
AML encompasses a family of hematologic malignancies that can be categorized according 
to their cytogenetic and associated genetic abnormalities, which have major prognostic 
importance. During recent years, considerable progress has been made in deciphering the 
molecular genetics and epigenetic basis of AML and in defining new diagnostic and 
prognostic markers. A growing number of recurring genetic changes have been recognized 
in the new WHO classification of AML. Furthermore, novel therapies are now being 
developed that target some of the genetic lesions and the treatment increasingly is being 
individualized by prognostic groups, with a goal of developing treatment tailored to the 
molecular basis of the patient's malignancy (Swerdlow et al., 2008). 
1.2.1 WHO classification of AML 
The current WHO classification of AML reflects the fact that an increasing number of new 
clinico-pathologenetic entities of AML are categorized based upon their underlying 
cytogenetic or molecular genetic abnormalities (Swerdlow et al., 2008). A number of 
recurrent genetic abnormalities are adequately defined and are recognized as entities of 
AML. The subgroup “AML with recurrent genetic abnormalities” is comprised of entities 
that are defined with seven recurrent balanced translocations and inversions, and their 
variants. Two entities  from this group: “AML with t(8;21)(q22;q22); AML1/ETO” and 
“AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBF/MYH11” are considered  as AML 
regardless of bone marrow blast counts. In “APL with t(15;17)(q22;q12); PML/RAR,” 
RAR translocations with other partner genes are recognized separately. The former 
category “AML with 11q23 (MLL) abnormalities” is redefined in “AML with 
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t(9;11)(p22;q23); MLLT3/MLL”, and now is a unique entity. Three new cytogenetically 
defined entities also are incorporated: “AML with t(6;9)(p23;q34);DEK-NUP214”, “AML 
with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1”; and “AML (megakaryoblastic) with 
t(1;22)(p13;q13); RBM15-MKL1,” a rare leukemia most commonly occurring in infants 
(Vardiman et al., 2008).  
Moreover, two new provisional entities defined by the presence of gene mutations between 
the group of cytogenetically normal AML (CN-AML) were added, “AML with mutated 
NPM1 (nucleophosmin),” and “AML with mutated CEBPA [CCAAT/enhancer binding 
protein(C/EBP), alpha].” There is growing evidence that these two gene mutations 
represent primary genetic lesions (so-called class II mutations), that impair hematopoietic 
differentiation, and when present alone in AML have favorable prognostic meaning. 
Mutations in the FMS-related tyrosine kinase 3 (FLT3) gene are found in many AML 
subtypes and are considered as class I mutations conferring a proliferation and/or survival 
advantage. AML with FLT3 mutations are not considered as a distinct entity, although 
determining the presence of those mutations is recommended by WHO because they have 
prognostic significance. The former subgroup termed “AML with multilineage dysplasia” is 
now designated “AML with myelodysplasia-related changes.” Dysplasia in 50% or more of 
cells, in 2 or more hematopoietic cell lineages, was the diagnostic criterion for the former 
subset (Schhlenk et al, 2008; Vardiman et al.,2008) 
However, the clinical significance of this morphologic feature has been questioned. AMLs are 
now categorized as “AML with myelodysplasia-related changes” if (1) they have a previous 
history of myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm 
(MDS/MPN) and evolve to AML with a marrow or blood blast count of 20% or more; (2) they 
have a myelodysplasia-related cytogenetic abnormality; or (3) if 50% or more of cells in 2 or 
more myeloid lineages are dysplastic (Swerdlow et al., 2008). 
“Therapy-related myeloid neoplasms” has remained a distinct entity; however, since most 
patients have received treatment using both alkylating agents and drugs that target 
topoisomerase II for prior malignancy, a division according to the type of previous therapy 
is not often feasible. Therefore, therapy-related myeloid neoplasms are no longer 
subcategorized. Myeloid proliferations related to Down syndrome are now listed as distinct 
entities (Döhner et al., 2010). 
A previous FAB classification is recognized in WHO classification as the entity AML, not 
otherwise specified. In this subgroup one can find the morphologic separation of AML 
according to the immaturity of leukemic cells as well as according to the hematopoietic 
lineage involved. This subtype of AML is reserved for the patients without the known 
cytogenetic or molecular genetic abnormalities. In some of them, there are markers 
associated with prognostic significance (Swerdlow et al., 2008; Vardiman et al, 2008).  
The rare forms of AML and acute leukemia of ambiguous lineage recognized in WHO 
classification are also associated with poor prognosis (Döhner et al., 2010; Vardiman et al., 
2008).  
1.3 Diagnostic procedures  
The diagnosis of the diverse subtypes of AML is a major challenge for modern hematology. 
Modern therapeutic concepts of AML are based on individual risk stratification in diagnosis 
and during follow-up. In the 1970s cytomorphology and cytochemistry represented the only 
available diagnostic tools. Nowadays, the routine diagnostic setting is completely changed 
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and it consists of classic cytogenetics, molecular cytogenetics, molecular genetics and 
immunophenotyping by multi-parameter flow cytometry (Döhner et al., 2010 ).  
1.3.1 Cytomorphology 
First steps in the diagnostic work-up of a patient with suspected AML is a morphological 
evaluation of a classical bone marrow aspirate and a peripheral blood smear by using a 
May-Grunwald-Giemsa or a Wright-Giemsa stain. It is recommended that at least 200 
leukocytes on blood smears and 500 nucleated cells on marrow smears to be counted. For a 
diagnosis of AML, a marrow or blood blast count of 20% or more is required, except for 
AML with t(15;17), t(8;21), inv(16) or t(16;16), and some cases of erythroleukemia. 
Myeloblasts, monoblasts, and megakaryoblasts are included in the blast count. Erythroblasts 
are not counted as blasts except in the rare instance of pure erythroid leukemia (Bennet et 
al,1997; Döhner et al., 2010; Panovska-Stavridis et al., 2008). 
1.3.2 Cytochemistry  
Lineage involvement could be identified with cytochemistry by using myeloperoxidase 
(MPO) or Sudan black B (SBB) and nonspecific esterase (NSE) stains. Detection of MPO (if 
present in > 3% of blasts) indicates myeloid differentiation, but its absence does not exclude 
a myeloid lineage because early myeloblasts and monoblasts may lack MPO. SBB staining 
parallels MPO but is less specific. NSE stains show diffuse cytoplasmic activity in 
monoblasts (usually 80% are positive) and monocytes (usually 20% positive). In acute 
erythroid leukemia, a periodic acid-Schiff (PAS) stain may show large globules of PAS 
positivity (Bennet et al,1997; Döhner et al., 2010, Panovska-Stavridis et al., 2008).  
1.3.3 Immunophenotyping 
Application of immunophenotyping together with the cytomorpohology and cytohemistry 
has a crucial role in the initial diagnosis of all cases with a suspected or proven diagnosis of 
acute leukemias. Immunophenotyping allows the discrimination of different cell population 
on the basis of their size, granularity, and antigen expression patterns. Flow cytometry is a 
powerful technology for characterization and analysis of cells. It simultaneously measures 
and analyzes multiple physical characteristics of single particles, usually cells, as they move 
in a fluid stream through a beam of light through an optical and/or electronic detection 
apparatus. Flow cytometry uses the principles of light scattering, light excitation, and 
emission of fluorochrome molecules to generate specific multi-parameter data from particles 
and cells in the size range of 0.5nm to 40nm diameter (Panovska-Stavridis et al., 2008).  
The applied methodology detects cell surface antigens in a suspension of viable cells and 
cytoplasmic and nuclear antigens in previously fixed and stabilized cell suspension with the 
application of monoclonal antibodies conjugated with different fluorochromes.  It permits 
simultaneous detection (multiparameter analyzes) of more than two membrane and nuclear 
or cytoplasmic antigens by means of double or multiple immunostaining (Bain et al., 2002;  
Bene et al., 1995; Döhner et al., 2010; Panovska-Stavridis et al., 2008).  
1.3.4 Cytogenetics 
Chromosome abnormalities are detected in approximately 55% of adult AML. Conventional 
cytogenetic analyses are part of the standard diagnostic approach of a patient suspected 
with AML. This allows the identification of genetics entities that deserve targeted treatments 
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like acute promyelocytic leukemia (APL). Also, it allows the distinction of the disease with 
widely different prognosis. For example AML t(8;21)(q22;q22) with favorable risk versus 
AML abn 3q26 with adverse risk (Döhner et al., 2010; Grimwade D.,2001).   
1.3.5 Molecular genetics 
Numerous genetic abnormalities that escape cytogenetic detection like gene mutations and 
gene expression abnormalities are more recently discovered among CN-AML. Molecular 
diagnosis by reverse transcriptase- polymerase chain reaction (RT-PCR) for the frequent gene 
fusions, such as AML1/ETO, CBFMYH11, MLLT3/MLL, DEK/NUP214, can also be useful 
in certain circumstances. RT-PCR, for which standardized protocols are already published, is 
also an excellent option to detect recurrent cytogenetic rearrangements, if chromosome 
morphology is of poor quality, or if there is typical marrow morphology but the suspected 
cytogenetic abnormality is not present. (Gabert et al., 2003; Beillard et al, 2003). 
1.4 Prognostic factors 
Prognostic factors of an AML case may be subdivided into those related to patient 
characteristics and general health condition and those related to characteristics particular to 
the AML clone. The former subset usually predicts treatment-related mortality (TRM) and 
becomes more important as patient age increases while the latter predicts resistance to, at 
least, conventional therapy. 
1.4.1 Patient-related factors 
Age, comorbidities, performance status and genetic variation in the drug metabolism are the 
main prognostic factors related to patients with AML. Increasing age is an important 
independent adverse prognostic factor (Appelbaum et al., 2006). Nonetheless, calendar age 
alone should not be a reason for not offering potentially curative therapy to an older patient 
because age is not the most important prognostic factor for either TRM or resistance to 
therapy. Currently all patients under the age of 60 are candidates to receive standard 
intensive chemotherapy and according to prognostic factors stem cell transplantation or 
intensive chemotherapy as postremission therapy. It has to be stressed that age as a factor is 
not only dependent on so-called „calendar age“. Recently many older patients with a good 
clinical status have been successfully treated with intensive chemotherapy. Attention should 
be given to a careful evaluation and documentation of comorbidities. Comorbidity scoring is 
a current field of investigation and should contribute to a better definition of the patient 
considered “unfit” for intensive chemotherapy (Piccirillo et al., 2004; Sorror et al., 2005).  
1.4.2 AML-related factors 
According to the AML working party of European Leukemia Net, several important and 
independent prognostic factors have been recognized:  white blood cell counts, existence of 
prior MDS or AML with MDS features, previous cytotoxic therapy for another malignancy, 
and cytogenetic and molecular abnormalities in leukemic cells (Döhner et al., 2010).  
1.4.2.1 Cytogenetics  
Chromosome abnormalities are detected in approximately 55% of adult AML. Although, there 
is a diversity of cytogenetic entities of AML, the karyotype of the leukemic cells is the strongest 
prognostic factor for response to induction therapy and for survival for AML patients 
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(Swerdlow et al., 2008). Younger adult patients are commonly categorized into 3 risk groups, 
favorable, intermediate, or adverse. The favorable group is represented by the reciprocal 
translocations t(15;17)/PML/RAR, t(8;21)/AML1/ETO, and inv(16)/CBFMYH11, which 
are associated with a favorable prognosis In contrast, AML associated with t(9;11)(p22;q23) 
shows an inferior prognosis. These subgroups represent the first hierarchy of the WHO 
classification of AML, emphasizing that these subtypes represent distinct biologic entities. The 
second subgroup of AML patients shows a normal karyotype and an intermediate prognosis. 
However, from molecular aspects, this subgroup is very heterogeneous. Lately, there are 
emerging data suggesting that two genetics entities from this group, the AML with mutation 
of NPM1 gene without FLT3 mutations and AML with mutation in CEBPA gene should be 
moved from the intermediate prognosis group to the favorable group of AML. Those two 
entities are also added to the new WHO classification (Schlenk et al., 2008). The third 
(prognostically unfavorable) subgroup includes mostly unbalanced karyotypes characterized 
by a gain or loss of larger chromosomal regions. Within these, an especially complex aberrant 
karyotype, which occurs in 10% to 12% of patients and that is defined by ≥3 chromosomal 
anomalies shows a very unfavorable prognosis. Cytogenetics is further helpful to delineate 
patients with therapy related AML (t-AML), who are classified as third hierarchy in the WHO 
classification, and developed either after treatment with alkylating agents often associated 
with cytogenetic aberrations involving 5q-, −7, or p53 and complex aberrant karyotype or are 
showing MLL/11q23 or other balanced cytogenetic aberrations which are in frequent 
association to previous treatment with topoisomerase II inhibitors One striking observation is 
the increasing incidence of adverse versus favorable cytogenetic abnormalities with increasing 
age. This, at least in part, contributes to the poorer outcome of AML in older adults.  (Byrd et 
al., 2002; Schlenk et al., 2008, Swerdlow et al., 2008)  
1.4.2.2 Molecular genetics 
Nowadays, considerable progress has been made in elucidating the molecular pathogenesis 
of acute leukemias that resulted in identification of new molecular diagnostic and 
prognostic markers.  Gene mutations and deregulated gene expression have been identified 
that allow us to interpret the genetic diversity within defined cytogenetic groups, in 
particular the large and heterogeneous group of patients with CN-AML. Risk stratification 
by molecular markers in patients from the former group of AML plays an increasing role at 
diagnosis. The most relevant markers, which can be detected alone or in coincidence with 
other mutation are NPM1 mutations that is detected in approximately 40% of cases, MLL-
PTD in 6%, NRAs in 8-10%, CEBPA in 10% and FLT3-TKD mutations in 6% of CN-AML. 
Thus, a rather of limited number of markers further subclassifies more than 85% of CN-
AML. Data from the literature suggest that those markers have different prognosis 
regarding the outcome of the disease and they all indicate that in the near future molecular 
screening may allow “ targeted allogeneic stem cell transplantation (alloSCT)” in AML 
patients  with normal karyotype (Schlenk et al., 2008; Koreth et al, 2009).  
There is a growing list of the new genetic abnormalities with clinical value that are being 
investigated. These genetic events perturb diverse cellular pathways and functions, and they 
often confer a profound impact upon the clinical phenotype of the disease and treatment 
response. 
It is anticipated that advances in molecular technology will reveal additional markers that 
will result in more precise classification of this heterogeneous complex of disorders 
(Löwenberg B., 2008b; Haferlach T., 2008) 
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1.5 Treatment  
The parallel progress of the development of the diagnostic techniques improvement of the 
classification and therapeutical approach lead acute leukemia which were for the first time 
described before 150 years, and in the 1970s were still fatal disease nowadays to have overall 
5 years survival rates of up to 40%. (Appelbaum et al, 2001). 
Despite heterogeneity of the disease, with the exception of acute promyelocytic leukemia, 
this disease has been treated with a “one size fits all” approach. Although, the vast majority 
of AML patients can be individually characterized on the basis of the distinct chromosomal 
aberrations and molecular markers, treatment of AML is still based on quite unspecific 
cytotoxic therapy. For almost 40 years, the use of continuous infusion of cytarabine 
combined with another agent, usually an anthracycline, the “3+7” regimen, has been the 
mainstay of therapy (Yates et al, 1973). Response rates for induction with standard 
chemotherapy ranged from 70% to 80% for adults aged less than 60years which are enrolled 
in clinical trials and average in 50% for patients older than 60 years (Lichtman et al.,2010) .  
Alternative consolidation therapies by applying additional chemotherapy, autologous stem 
cell transplantation (autoSCT) or alloSCT based on the initial cytogenetic and molecular 
studies are available (Cornelissen J.J.et al.(2007); Fernandez H.F.,2010; Koreth et al, 2009)  
As more sophisticated molecular techniques have become available, it is clear that it is still 
possible to detect residual disease when all morphological and functional criteria for 
remission are met. Techniques such as “real–time”-quantitative polymerase chain reaction 
(RQ-PCR) are capable of detection at a level of 1 in 104 or 1 in 105 residual cells, but such 
markers are available for only a minority of cases in which the molecular lesion has been 
characterized(Freeman et al., 2008). 
AlloSCT is the most effective antileukemic modality that is characterized by immune mediated 
graft-versus-leukemia effect of the transplanted cells that reduce the risk of relapse 
considerably and improve the relapse-free survival but also is associated with the increased 
risk of death and morbidity. Therefore, the alloSCT advantage has to be carefully balanced 
against the excess mortality (ranging between 10% and 40%) and morbidity due to transplant-
related complications, such as infection and graft-versus-host disease that are typically 
connected with alloSCT and can diminish all of the benefit of a reduced risk of relapse. 
(Cornelissen et al., 2007). For this reason, allogeneic stem cell transplantation is usually 
avoided in a type of AML that has a pattern of cytogenetics with a relatively favorable 
prognosis, such as AML with the chromosomal translocations t(8;21) or 
inv(16)/t(16;16)(Marcucci et al., 2000; Perea et al.,2006). In the latter subtypes the risk of relapse 
is in the order of 35% to 40% or less. By contrast, a transplant is treatment of choice for all other 
patient whose leukemia cells bear a cytogenetic or molecular abnormality that predicts a high 
or intermediate risk of relapse after chemotherapy (Löwenberg et al., 2008b; Koreth et al, 2009). 
Exception could be done for two additional genotypically defined subsets of AML that are 
categorized as low-risk within the large category of CN-AML. Each of those entities has a 
risk of relapse of about 35%. The first genotype is defined by the presence of ‘favorable’ 
mutations in NPM1 and the absence of concurrent ‘unfavorable’ FLT3-internal tandem 
duplications (NPM1mut /FLT3-ITDneg).61 This genotype accounts for approximately 16% 
of all newly diagnosed patients  younger than 60 years old. There is no demonstrable benefit 
from transplantation in patients with NPM1mut/FLT3-ITDneg AML. The second subset of 
AML with ‘favorable’ mutations in the transcription factor gene CEBPA (CEBPAmut) could 
not be analyzed in this way because of a lack of statistical power due to a limited number of 
cases. The latter low-risk subtype CEBPAmut accounts for 8% of all AML. Nevertheless, the 
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available body of evidence suggests that these AMLs are unlikely to profit from an alloSCT 
(Schlenk et al., 2008).  
Thus, it could be concluded that patients with AML with t(8;21), AML with inv(16)/t(16;16), 
AML with NPM1mut/ FLT3-ITDneg and AML with CEBPA mutations should not 
considered for alloSCT. Nevertheless, it is important to stress that sufficient evidence so far 
exist only for the AML with recurrent cytogenetic abnormalities and the benefits for the two 
additional genetic low-risk AML entities should be validated in the larger studies in the 
future (Schlenk et al., 2008). 
 In the near future these results will also need to be considered more specifically in the light 
of the extended scale of allogeneic stem cell transplantation strategies with respect to 
reduced-intensity conditioning regimens and in relationship to different transplant sources 
and donor types (matched unrelated and haploidentical donors, umbilical stem cell 
grafts).(Löwenberg et al, 2008a) 
2. Motivation and aim of the study 
Correct diagnosis of the diverse subtypes of acute myeloid leukemia (AML) and acute 
lymphoblastic leukemia (ALL) play a central role for individual clinical risk stratification 
and therapeutic decisions.  Modern therapeutic concepts of AML are based on individual 
risk stratification at diagnosis and during follow-up. The ultimate test of any disease 
diagnostic algorithm approach is its usefulness in guiding the selection of effective 
treatment strategies. (Haferlach et al., 2007, Löwenberg et al, 2008b) As discussed above, 
cytogenetic as well as various genomic markers (gene mutations, gene overexpression) may 
provide input for algorithms for remission induction and post-remission treatment 
decisions. At the same time, it remains appropriate to realize that prognostic factors in fact 
remain a moving target and they are only relevant to therapies available at a given time. 
Algorithms that provide a basis for risk-adapted therapeutic choices may include 
immunological markers, cytogenetic factors, molecular markers as well as clinical 
parameters (e.g., age, attainment of an early or late complete remission) and hematological 
determinants (e.g., secondary AML, white blood cell count at diagnosis). 
On the other hand, the more carefully AML is studied, the clearer it becomes that  there is 
considerable heterogeneity between cases with respect to morphology, immunological 
phenotype, associated cytogenetic and molecular abnormalities and, more recently, patterns 
of gene expression. This is reflected in the substantially different responses to treatment. 
Some entities are becoming so distinct that they are regarded as different diseases with 
specific approaches to treatment. 
In order to improve and simplify the diagnosis and management of AML patients that are 
diagnosed and treated at the at the University Clinic of Hematology-Skopje we conducted a 
prospective study to establish and standardize a diagnostic algorithm based on minimal 
screening tests which will facilitate risk adapted therapy for each single AML patient. The 
aims of our study were: first, to establish the correct lineage assignment of the blast cells, 
second, to evaluate the incidence of the favorable genetic markers PML/RAR, AML1/ETO 
and CBF/MYH11 among the AML cases, then to correlate the obtained results with the 
patient age, comorbidities, and performance status and consecutively to select the effective 
treatment strategy for each single acute leukemia patient. 
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3. Material and methods  
3.1 Patients and samples 
A total of 76 adult (>15 years) patients (from initially 77 tested) with acute leukemia who were 
consecutively admitted at the Clinic of Hematology-Skopje from January through December 
2008 were enrolled in this study. The median age of the patients (41 men, 35 women) was 52 + 
18.66 years (range 16-80), and most of the patients 37 (48.7%) were between 55 and 75 years 
old. The diagnosis was made by standard morphological examination and cytochemical 
analyses of bone marrow smears according to the criteria established by the FAB Cooperative 
Study Group (Bennet et al, 1997) and confirmed by immunophenotyping of bone marrow 
aspirates and/or peripheral blood samples (Bain et al., 2002;  Bene et al., 1995 ) following the 
criteria of the European Group for the Immunological Classification of leukemias (EGIL) and 
the British Committee for Standards in Hematology (BCSH) (Bain et al., 2002;  Bene et al., 
1995).  Consecutively, patients were further stratified in the adequate genetic AML entities 
according to the results of the molecular analyses. The samples contained more than 20% of 
blast cells (most of which had more than 50%). All patients were tested for the presence of the 
fusion transcript of the mayor recurrent cytogenteic abnormalities in AML (PML/RAR, 
AML1/ETO, CBF/MYH11) by RT-PCR, according to standard procedures. (Gabert et al.2003; 
Beillardet al, 2003).  
 
 
Fig. 1. Average age of the patients in the study group  
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3.1.1 Clinical data from the patients 
Clinical data from the patients were collected according the internal protocol that was 
approved by the University Clinic of Hematology Institutional Review Board. All included 
patients had to sign a written consent.  
3.2 Morphology 
The morphology was analyzed by microscopic examination of >500 nonerythroid cells on 
May Gruenwald Giemza stained air-dried bone marrow smears (Bennet et al,1997; Döhner 
et al., 2010; Panovska-Stavridis et al., 2008).  
3.3 Cytochemical analysis 
Air-dried bone marrow smears were stained for MPO, non specific esterase (NSE) and 
periodic acid-Schiff (PAS) according to the manufacturers guidelines. The percentage of 
positive cells for either stain was assessed by microscopic examination of 200 nonerythroid 
cells (Bennet et al, 1997; Döhner et al., 2010; Panovska-Stavridis et al., 2008). 
3.4 Immunophenotyping 
The muliparameter flow cytometry (MPF) was performed at the beginning at the Institute 
for Immunobiology and Human Genetics, Faculty of Medicine-Skopje and then continued at 
the University Clinic of Hematology-Skopje. Immunophenotyping was done first, by using 
Cytomation (DAKO-Cytomation) flow-cytometer and than by BD FACSCanto™ II analyzer, 
on whole blood and/or bone marrow specimens using lysing solutions (BD-Biosciensies, 
San Jose.CA. USA)(Bain et al., 2002). We prepare the samples for simultaneous detection of 
three cytoplasmic/nuclear and membrane antigens. The first step involved immunostaining 
of cell suspension with multiple panels of tree monoclonal antibodies (McAb) labeled with 
fluorescein (FITC), phycoerythrin (PE) and phycoerythryn-Cy5 tandem complex (Pe-Cy5) as 
third color (Panovska-Stavridis et al., 2008). The slightly modified panel of monoclonal 
antibodies (McAb) against myeloid- and lymphoid-associated antigens as suggested by the 
EGIL was utilized (Bain et al., 2002; Panovska-Stavridis et al., 2008). The antibodies and their 
manufacturers are listed in Table 1. 
 
 B-lineage T-lineage Myeloid markers 
Non-lineage 
restricted 
First line 
CD19, 
cyt CD79b, 
cyt CD22 
CD 2, CD7, 
cyt CD3 
CD117,CD13, 
CD33,CD14, CD15, 
anti-MPO,         
anti-lisosyme 
TdT, CD34, 
HLA-DR, CD 56 
Second line 
SmIg 
(kappa/lambda)**, 
cytIgM2,CD138 
CD1a,mCD31, 
CD4,CD5,CD8, 
anti TCR  
anti TCR 
CD41, CD61, 
CD42,CD71 
Anti-glycophorin A 
CD38 
All markers were manufactured by BD-Biosciences, except antilysozyme (DAKO); 1.cyt: cytoplasmic;   
2.m: membrane  *MPO: myloperoxidase;** SmIg:surface immunoglobulin;*** TCR:T cell receptor  
Table 1. Panel of monoclonal antibodies (McAb) for diagnosis of acute leukemias  
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For the detection of cytoplasmic and nuclear antigens we used commercially available 
permeabilization/fixation solutions (FACS Permeabilization solution BDBiosciencies;San 
Jose.CA.USA) ((Bain et al., 2002). 
We incubated 100ml of specimens (peripheral blood or bone marrow) and appropriate 
McAb for 15min at room temperature, than added the permeabilization solutions and/or 
lysing solution and repeated the incubation procedure. After the incubation we washed the 
samples three times with PBS-A, than re-suspended the cell with isotones solution and 
acquired the data. As control we used a lysed, but unstained sample (Panovska-Stavridis et 
al., 2008) 
Acquired data were analyzed with software by using CD45 gating strategy (Borowitz et al, 
1993). This technique involves incubation of all samples with fluorochrome - labeled CD45 
McAb and with the McAb for which reactivity needs to be established with an alternative 
fluorochrome). In the initial step of the analyses, gating was set up on a CD45-positive 
versus light side-scatter dot plot. The procedure allowed the discrimination between the 
blast cell population and normal cells and the exclusion of platelets and debris. Thereafter, if 
necessary, it was possible to perform another gating, to separate the cells positive with the 
McAb under study (Borowitz et al, 1993). Leukemias were first screened by the primary 
panel and, if necessary, further characterized by the McAb of the secondary panel (Bain et 
al., 2002). 
Antigen expression was considered positive if 20% or more blast cells reacted with a 
particular antibody, except reactivity of blasts cells with MPO. It was considered positive if 
10% or more of mononuclear cells were MPO positive (Bain et al., 2002; Döhner et al., 2010).  
3.5 Molecular analysis 
Mononuclear cell preparation, RNA isolation, and cDNA synthesis were performed at the 
Department of Molecular Biology, Immunology and Pharmacogenetics, Faculty of 
Pharmacy-Skopje, according to standard procedures. Aliquots of 5 μL of cDNA (100 ng 
RNA equivalent) were used for Real-time Quantitative polymerase chain reaction (RQ-PCR) 
with primers and dual-labeled probes as described by Gabert et al. Positions and nucleotide 
sequences of the primers and probes are shown in Table 2. 
The RQ-PCR reaction was performed in a 25-μl reaction volume using 12.5 μl (1x) Master 
Mix (Applied Biosystems), 300nM primers and 200nM probes on a Mx3005P(TM) QPCR 
System (Stratagene) under the following conditions: 95C for 10min, followed by 50 cycles of 
95C for 15s, 50C for 1min. In order to correct variations in RNA quality and quantity and 
to calculate the sensitivity of each measurement, a control gene (CG) transcript was 
amplified in parallel to the fusion gene (FG) transcript. Since ABL (Abelson) gene transcript 
expression did not differ significantly between normal and leukemic samples, ABL was 
used as a control gene in this study (24). Positions and nucleotide sequences of the primers 
and probe are shown in Table 2. 
3.6 Statistical analysis 
Statistical analyses were performed by using the statistical analyses software SPSS 18.0 and 
by applying the Descriptive statistics (cross tabulation, frequencies, descriptive ratio 
statistics), bivariate statistics (means, t-test, correlation (bivariate, partial, distances), 
nonparametric tests and linear regression statistical methods.  The Level of probability for 
obtaining the null hypothesis, in accordance with the international conventions for bio-
medical sciences was 0.05 or 0.01 (Armitage et al., 2002). 
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Transcript EAC codea Primer/probe 
localization, 
5'–'3’ position 
(size) 
Sequence  
AML1 
/ETO 
ENF701 AML1, 1005–1026 
(22) 
5'–CAC CTA CCA CAG AGC CAT CAA A–3' 
ENR761 ETO, 318–297 (22) 5'–ATC CAC AGG TGA GTC TGG CAT T–3' 
ENP747 AML1, 1049–295 
(30) 
FAM 5'–AAC CTC GAA ATC GTA CTG AGA AGC 
ACT CCA–3' TAMRA 
PML 
/RARα 
ENF905 PML, 1198–1216 
(19) 
5'–CCG ATG GCT TCG ACG AGT T–3' 
ENF906 PML, 1642–1660 
(19) 
5'–ACC TGG ATG GAC CGC CTA G–3' 
ENF903 PML, 1690–1708 
(19) 
5'–TCT TCC TGC CCA ACA GCA A–3' 
ENR962 RARA, 485–465 
(21) 
5'–GCT TGT AGA TGC GGG GTA GAG–3' 
ENR942 RARA, 439–458 
(20) 
FAM 5'–AGT GCC CAG CCC TCC CTC GC–3' TAMRA 
CBF 
/MYH11 
ENF803 CBFB, 389–410 (22) 5'–CAT TAG CAC AAC AGG CCT TTG A–3' 
ENR862 MYH11, 1952–1936 
(17) 
5'–AGG GCC CGC TTG GAC TT–3' 
ENR863 MYH11, 1237–1217 
(21) 
5'–CCT CGT TAA GCA TCC CTG TGA–3' 
ENR865 MYH11, 1038–1016 
(23) 
5'–CTC TTT CTC CAG CGT CTG CTT AT–3' 
ENPr843 CBFB, 434–413 (22) FAM 5'–TCG CGT GTC CTT CTC CGA GCC T–3' 
TAMRA 
ABL ENF1003 ABL, 372–402 (31) 5'-TGGAGATAACACTCTAAGCATAACTAAAGGT–3' 
ENF1063 ABL, 495–515 (21) 5'–GATGTAGTTGCTTGGGACCCA–3' 
ENF1043 ABL, 467–494 (28) FAM 5'–CCA TTT TTG GTT TGG GCT TCA CAC CAT 
T–3' TAMRA 
aENF = forward primer, ENR = reverse primer, ENP = TaqMan probe 
Table 2. Sequences and positions of the RQ-PCR primers and probes  
4. Results  
In the period of twelve months, between January and December 2008, 77 patients were 
submitted and tested for acute leukemia at the University Clinic of Hematology-Skopje. 
Cyto-morphological analyses showed that the average rate of the blast cells in the 
differential blood counts and in the bone marrow was 54.6%(3-99.0%) and 73,5%(20-98.0%) 
respectively. In 7 patients blast cells were not detected initially.  
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4.1 Results from the cytochemical analyses 
Results from the cytochemical analyses and the images of peripheral smears with positive 
examples from different cytochemical staining are presented at Figure 2 and Photo 1 
respectively.  
 
 
A 
 
 
B 
 
 
C 
Fig. 2. Distribution of patients according to reactivity with different  cytochemial staining.  
A:Patient distribution according to MPO reactivity of the blasts cells. B: Patient distribution 
according to PAS reactivity of the blasts cells. C: Patient distribution according to NSE 
reactivity of the blasts cells.  
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C 
Photo 1. Images from positive reactivity of peripheral blast cells with different cytochemical 
staining , A: PAS reactivity, B: POX reactivity, C: NSE reactivity 
Statistical analyses showed that there is a statistically significant correlation between the 
AML and MPO positivity (X2 with Yates’s correction=16.628 p<0.01)(Figure 2A). According 
to cross reaction ratio, MPO positivity presents statistically significant risk which improves 
the chance of AML diagnosis for 39 times (OR=392.1603 (4.177<0R<305.9796, CI 95%)). Also, 
a statistically significant correlation was noted between the PAS positivity and ALL (X2 with 
Yates’s correction=5.514 p<0.01)( Figure 2B). Strong PAS positivity was registered in 75% of 
ALL cases. Regarding the cytochemical stain NSE and AML no statistical correlation was 
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observed (X2 with Yates’s correction=2.456 p=0.117), expect for AML M4 and M5 entities 
which showed statistically significant correlation (p<0, 05) (Figure 2C).  
Morphology and cytochemistry established myeloid lineage in 57 (74.0%) cases and 
lymphoid differentiation in 11 (14.3%) cases (Figure 2). Morphology and cytochemistry did 
not establish lineage involvement in 9 (11.7%) cases. Basic morphological and cytochemical 
analyses established the lineage assignment of the blasts cells in 68 (88.3%) patients. 
 
 
Fig. 3. Distribution of cases based on lineage assignment of blasts cells detected with basic 
morphological and cytochemial analyses  
4.2 Results from the immunological analyses 
Immunological analyses with multi-parameter flow-cytometry were performed in all 77 
patients.  Further immunological analyses of cases in which lineage could not be assigned 
based on morphology and cytochemistry established myeloid lineage in 4 patients, (AML-
M0) and one case indicated nonhematopoietic malignancy. In this case, immunophenotype 
of the malignant cells (CD45-/CD56+/CD9+) indicated a neuroectodermal origin of the 
malignant cells (Bain et al., 2002). Later neuroblastoma was diagnosed in this patient. 
Immunological analyses change the assigned lineage based on morphology and 
cytochemistry in 3(3.8%) of the patients from lymphoid to myeloid. The results of our study 
showed that routine immunophenotyping improved diagnosis in 12 (15.5%) cases. 
Consequently, based on FAB and immunologic criteria of EGIL and BTSH 64 acute 
leukemias were classified as myeloid. Correlation between the antigen expressions with 
FAB morphology of AML cases which confirmed the AML diagnosis in 83. 1% of the cases is 
presented at Table 3. According to FAB criteria, the leukemias were classified as M0 (n=4), 
M1 (n=8), M2 (n=20), M3 (n=5), M4 (n=17), M4-Eo (n=1), M5 (n=8), M6 (n=1).  
Multivariate Cox-proportional regression analyses showed that in 89.7% of AML cases 
lineage assignment is defined with the following five markers: CD13, CD33, CD117, HLA-
DR and anti-MPO. Most frequently detected maturation myeloid marker which was 
expressed in 42.9% of AML case was CD15.  Twenty three (35.9 %) of AML patients showed 
expression of lymphoid antigens. Co-expression of two lymphoid markers was detected in 
eleven (17.1%) cases, and most frequently co-expressed lymphoid marker was CD7 and was 
detected in 28.5% of the cases. 
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Table 3. Correlation between the antigen expressions with FAB morphology of AML cases 
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4.3 Results from the molecular analyses 
Molecular evaluation of AML cases demonstrated presence of the three major recurrent 
genetic abnormalities as follows: 5 patients were positive for the fusion transcript 
PML/RAR  (Figure 5), 3 patients were positive for AML/ETO1 and 7 for the fusion 
transcript CBF/MYH11 (Figure 4).  
 
 
Fig. 4. Distribution of molecular abnormalities detected with the RQ-PCR  assay in the 
group of AML patients;  
 
 
 
Fig. 5. Detection of fusion transcript PML/RAR using the RQ-PCR method 
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In 5 of the AML case PML/RAR fusion transcript was detected. Four of those patients had 
morphology and immunophenotype that correlate with AML-M3 diagnosis. The five 
patients were first diagnosed as AML-M2 and only after the positive result for PML/RAR 
the diagnosis was revised as AML-M3.  In all those five patients target therapy with ATRA 
was initiated. 
RT-PCR analysis also detected molecular abnormalities in the Core binding factor (CBF) in 
10 AML patients; the presence of the AML/ETO1 fusion gene was confirmed in 3 patient 
and CBF/MYH11 in 7 patients.  
Molecular analyses enabled 23.7% of the cases from our study to be classified in the 
adequate genetic entities of AML with different prognosis requiring different therapeutic 
approach. 
4.4 Results from the analyses of the clinical data of the patients 
We evaluate the distributions of the patients from our study group in the different grades of 
the Eastern Cooperative Oncology Group (EKOG) performance status scale (Oken et al. 
1982)(Figure 6). All the patients with EKOG performance status higher than grade 2 and 
patients with serious co morbidities were not suitable candidates for alloSCT.  
Furthermore, all the obtained results were correlated and consecutively effective treatment 
strategy for each single acute leukemia patient was selected.  
5. Discussion 
Modern diagnostic approach for acute leukemias combines cytomorphology, cytochemistry, 
multiparameter flow cytometry, chromosome banding analysis, accompanied by diverse 
fluorescence in situ hybridization techniques, and molecular analyses. The correct diagnosis 
is essential for classification of this heterogeneous complex of disorders and plays a central 
role for individual risk stratification and therapeutic decisions (Haferlach et al., 2007; 
Lichtman et al., 2010) 
 
 
Fig. 6. Distribution of patients according to the grades of the EKOG performance status  
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5.1 Immunophenotyping in modern diagnosis of AML 
Assignment of lineage is critical in the diagnostic evaluation of acute leukemia, as treatment 
for AML and ALL markedly differs. Myeloid and lymphoid lineage may be distinguished 
based on cellular morphology, cytochemical staining, and expression of lineage-specific 
antigens (Döhner et al., 2010). Analyses of diagnostic evaluation of acute leukemia in our 
study showed that immunophenotyping was necessary for lineage assignment in 4 (8.9%) 
cases that were morphologically and cytochemically undifferentiated, and also for 
correction of the lineage that was assigned based on morphology and cytochemistry in 
3(3.8%) additional cases.  
Flow cytometric immunophenotyping is a powerful technological tool that aids in the 
diagnosis, classification and monitoring of hematological malignancies. It is essential in the 
diagnosis of AML, as it demonstrates a particular lineage involvement and has a prognostic 
significance in the majority of AML cases. We used the panel based on the recommendation 
of the EGIL group and BTSH. Our analyses comprised of a two step process with the first 
panel of markers being applied to all cases of acute leukemia and the second only in patients 
with AML that did not demonstrate a clear myeloid commitment. We also evaluated further 
lymphoid antigen positive AML cases by using the second panel of McAb (Stelzer & 
Goodpasture, 2000).  
The second panel of McAb was aimed at identifying uncommon types of AML, such as 
those with megakaryocytic or elytroid differentiation and the exclusion or conformation of 
diagnosis of non-hematological malignancy. In our study, we applied the second AML 
panel in 27 cases; 4 which did not demonstrate clear myeloid commitment and 23 cases with 
lymphoid antigen positive AML cases. With our primary McAb we were able to 
differentiate AML form ALL in 96.8% of cases. Only in one patient (AML-M6-1.5%) lineage 
differentiation was assigned after staining with the secondary McAB panel and one case of 
non-hematological malignancy was confirmed. 
Immunophenotyping was crucial in all cases of poorly differentiated myeloid leukemia 
(AML-M0), megakaryoblatstic leukemia (AML-M7) and in some case of monoblastic 
leukemia (AML-M5) and those with primitive erythroid cells as predominant leukemic cells 
(AML-M6). This is also important for recognizing an AML case that co-expresses lymphoid-
associated antigens. In addition, immunophenotyping enables recognition of unusual forms 
of acute leukemia: designated acute biphenotypic or acute mixed lineage leukemia. The 
leukemia associated immunophenotype (LAIP) of the blast cells is a useful tool for detection 
of minimal residual disease in AML cases (Döhner et al., 2010; Stelzer & Goodpasture, 2000; 
Swerdlow et al., 2008).   
In order to classify AML cases in the different AML entities we correlated the 
immunological data from immunophenotyping with the FAB morphological and 
cytochemical classification. One of the difficulties in knotting the flow cytometric data with 
traditional morphology is the lack of routine flow cytometric data analyses that would 
ensure correlation of the immunophenotyping data to abnormal morphologic counterpart. 
Our approach was based on the fact that complete eight-part differential of the myeloid 
lineage in the normal bone marrow could be done with correlations of the expression of 
CD45 expression versus light side scatter (SSC) characteristics of the cells. Extension of this 
technique to the analyses of leukemias allows abnormal cell to be recognized as 
independent clusters in CD45/SSC histograms with pattern of CD45 and SSC expression 
that correlate to the same pattern of the morphologically similar cells in normal bone 
marrow. Flow-cytometric analyses by using CD45 gating strategy reveled that leukemic 
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myeloblasts demonstrate very similar CD45/SSC characteristics to normal myeloblasts, 
especially the early myeloblasts. In fact, leukemic cells generally demonstrate CD45/SSC 
characteristics that closely resemble their nearest normal morphological counterparts in the 
bone marrow. In the histograms the leukemic cells can be easily recognized as an abnormal 
cluster of cells in CD45/SSC „space” which is usually occupied by normal myeloid blasts. 
Using this method we define in our study group each category of AML as defined by FAB 
system (Stelzer & Goodpasture, 2000). Early myeloblasts are presented at Figure 6. Flow 
cytometric analyses show that those leukemic cells demonstrate low light forward and side 
scatter (FSC&SSC), which means that those cells are small and don’t contain any granules. 
They also have low CD45 expression.  
The predominant immunophenotype characteristics of early myeloblasts are an expression 
of all pan-myeloid antigens: CD13, CD33, CD117 and HLA-DR and lack expression of more 
mature myeloid antigens such as CD15 and CD14. Also, high proportion of the leukemic 
cells expresses CD34. With the maturation process of the blast cells, CD34 expression 
becomes more heterogeneous and weaker. The densest is at AML-M0 blasts, which typically 
express only one myeloid-associated antigen plus. Myeloid blasts that arise as a result of the 
genetic change in more mature myeloid progenitor lose the characteristics of the early 
myeloblasts. For example, AML-M3 blasts usually lack the expression of CD34 and HLA-
DR.  
At Figure 7 are presents more mature myeloblasts, M5 blast. It is obvious that they are 
bigger when compared with the AML-M1 blasts presented on Figure 6, and contain some 
more granules (have higher FSC&SSC). Immunophenotypically, they are characterized with 
expression of some more mature myeloid markers as CD14 and CD15, and in most of the 
case with lost CD34 expression.   
The results from our study showed that routine immunophenotyping improved the diagnosis 
in 12 (15, 5%) cases with acute leukemia which was essential for more appropriate individual 
clinical stratification of the patient with acute leukemia. Our data demonstrate that flow 
cytometry in correlation with the morphological classification criteria for each subtype of AML 
can be used for initial classification of each FAB AML entities and and justify routine 
implementation of flow cytometry analyses in the diagnostic evaluation of AML cases. 
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Fig. 6. Histogram analyses of early M1 myeloblasts ; A: Blast cells demonostrate low 
FSC&SSC, B:Blast cells have low CD45 expression 
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Fig. 7. Histogram analyses of M5-myloblasts; A: Blast cells are biger and more granular and 
have higher CD45,B: Blasts cells express CD117 and the myeloid expression  maturation 
marker CD15  
5.2 Molecular analyses in the modern diagnosis of AML 
Results from the immunophenotying guided us to perform exact molecular analyses and 
further define some specific genetic entities of AML. We tested our AML patients for the 
presence of PML/RAR, AML1/ETO and CBF/MYH11 fusion transcripts, by using RT-
PCR method. Results from those analyses additionally improved the exact classification of 
the AML subtypes and made target and specific therapy available for some of the specific 
AML subtypes (Marcucci et al., 2000; Perea et al.2006; Wang et al., 2008)   
Nonrandom chromosomal abnormalities are identified at the cytogenetic level in 
approximately 55% of all adult primary or de novo AML patients and have long been 
recognized as important independent prognostic indicators for achievement of complete 
remission (CR), duration of first CR, and survival after intensive chemotherapy treatment. 
Two of the most prevalent cytogenetic subtypes of adult primary or de novo AML are t (8; 
21) (q22; q22) and inv (16) (p13q22). These abnormalities result in the disruption of genes 
encoding subunits of the CBF, which is a  heterodimeric transcriptional factor involved in 
the regulation of normal hematopoiesis and are collectively referred as CBF-AML. At the 
molecular level, t(8;21)(q22;q22) and inv(l6)(p13q22) result in the creation of novel fusion 
genes, AML1/ETO and CBF/MYH11.Detection of t(8;21)(q22;q22) or inv(16)(p13q22) in 
adult patients with primary AML is a favorable independent prognostic indicator for 
achievement of cure after intensive chemotherapy or bone marrow transplantation, and may 
serve as a as a paradigm of the risk-adapted treatment in AML (Döhner et al. 2010&  
Marcucci et al., 2000).  
In almost all studies of adult primary AML, the highest CR rate (approximately 90%) and 
the longest disease free survival (DFS) at 5 years (approximately 50%) have been associated 
with CBF-AML cases. It has been suggested that the superior outcome of AML patients with 
CBF gene rearrangements compared with other AML patients may be attributed to an 
increased sensitivity of the leukemic blasts to cytarabine that in combination with 
anthracyclines represents the backbone of AML treatment. The collective analysis of all data 
regarding the treatment of CBF-AML indicates that incorporation of multiple courses of 
high dose of cytarabine as consolidation therapy should be considered as the therapeutic 
standard for primary adult CBF-AML (Marcucci et al., 2001; Perea et al.2006). 
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The prognostic impact of the CBF gene rearrangements appears equally significant in the 
setting of BMT of AML patients in first CR. However, the iatrogenic morbidity and 
mortality of BMT suggest that patients with CBF-AML should not receive this therapeutic 
modality as initial treatment. The collective analysis of all data regarding the 
implementation of all SCT in AML treatment suggest that although allo SCT and auto SCT 
may have a potential role in the initial management of AML other than CBF-AML, the 
treatment-related morbidity and mortality of SCT represent a therapeutic limitation for 
treatment of CBF-AML patients. Considering the high probability of cure that these patients 
can achieve with intensive chemotherapy, it is reasonable to spare them the toxicity of SCT 
as consolidation in first complete remission (Löwenberg et al., 2008a; Koreth et al, 2009; 
Marcucci et al., 2000; Marcucci et al., 2001 & Perea et al.2006). 
APL or AML-M3 is a distinct subtype of AML which is characterized by a t(15;17) 
translocation leading to a PML-RARA fusion gene. Historically, recognition of this form of 
AML as a separate entity was important for the clinicians, not because the chemotherapy 
used as treatment differed substantially from that used for the other subtypes of AML, but 
because the relatively common occurrence of life-threatening coagulopathy mandated 
special supportive maneuvers, including the use of low-dose heparin and aggressive 
blood product support. In the past, induction mortality was often significant, with some 
older series reporting an incidence approaching 50%. APL was typified with the worst 
features associated with leukemia: a fulminant disorder that struck primarily young 
people, had devastating effects on an individual's life, and resulted in death for a large 
number of patients during the initial phases of treatment. The last two decades have seen 
a fundamental shift from this paradigm, with APL now recognized as one of the most 
curable forms of acute leukemia. Introduction of the differentiation therapy with ATRA 
into the treatment of APL completely revolutionized the management and outcome of this 
disease, and presents the first model of targeted therapy for cancer. This agent represents 
one of the most spectacular advances in the treatment of human cancer, providing the first 
paradigm of molecularly targeted treatment. Treatment of APL with ATRA combined 
with anthracycline-based chemotherapy yields a CR rate of approximately 90% for newly 
diagnosed APLs. The relapse rate is approximately 20%, and with the development of 
new molecular target therapies such as arsenic trioxide, a cure can now be expected even 
for relapsed patients. After the advent of ATRA, the introduction of arsenic trioxide 
(ATO), probably the most biologically active single drug in APL has provided a valuable 
addition to the armamentarium and may have contributed to further improvements in the 
clinical outcome of this disease. Several treatment strategies using these agents, usually in 
combination with chemotherapy, have provided excellent therapeutic results with 
survival rates exceeding 70% in multicenter clinical trials. Cure of patients with APL 
depends not only on the effective use of combination therapy involving differentiating 
and classical cytotoxic agents, but also, critically, upon supportive care measures that take 
into particular account the biology of the disease and the complications associated with 
molecularly targeted therapies. Moreover, it is important to consider diagnostic suspicion 
of APL as a medical emergency (uncommon in AML) that requires several specific and 
simultaneous actions, including immediate commencement of ATRA therapy, prompt 
genetic diagnosis, and measures to counteract the coagulopathy (Grimwade et al., 2002; 
Wang et al., 2008). 
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5.2.1 Why we used RT-PCR method for detection of the genetic abnormalities? 
RT-PCR methods for detecting the PML/RARfusion transcript also provide the “gold 
standard” approach for confirming a diagnosis of APL. In addition to its high specificity and 
sensitivity, it is essential for defining PML breakpoint location thereby establishing the 
target for reliable monitoring of the minimal residual disease (MRD). 
Standard cytogenetic analysis is currently the most common method for identifying the 
most common recurrent cytogenetic abnormalities t(8;2l)(q22;q22) and inv( 16)(pl3q22) or 
t(16;16)(p13;q22) in AML patients. This technique also allows detection of secondary 
chromosomal abnormalities such as del (9q),-X and -Y which are frequently associated with 
t(8;21)(q22;q22), or +8 and +22 more often found with inv(16)(p13q22). Still, despite the 
recent improvements in the cytogenetic methodology and the use of complementary 
techniques such as fluorescence in situ hybridization and comparative genomic 
hybridization to increase the rate of successful karyotyping, the possibility that subtle 
structural chromosomal aberrations are missed remains (Marcucci et al., 2000). In t(8;21) 
(q22;q22) or inv(16) (p13q22), failure to detect submicroscopic (cryptic) rearrangements of 
the involved genes leads to false-negative results that may ultimately impact the correct 
stratification of this patient population in prognostic and risk-adapted therapy groups. 
Sensitive molecular methodologies such as RT-PCR have been successfully used to detect 
cryptic CBF abnormalities in diagnostic samples of AML patients with karyotypes that are 
otherwise negative for t(8;21)(q22;q22) or inv(16)(p13q22). Andrieu et al.,1997 reported 
detection of AML1/ETO fusion transcripts by RT-PCR in cases with unsuccessful 
cytogenetic studies, normal karyotypes, or karyotypes other than t(8:2 l)(q22;q22) such as 
del(8q), i(8)(q10) or del(9q). Langabeer et al., 1997 used a two-step RT-PCR to screen for the 
AMLI/ETO and CBF/MYHll fusion transcripts in AML patients entered into the U.K. 
MRC AML 10, 11, and 12 trials and compared the results with conventional cytogenetics. All 
patients with cytogenetic evidence of t(8;21)(q22;q22) or inv(16)(pl3q22) were positive by 
RT-PCR for the corresponding fusion transcripts. RT-PCR was also positive in 31 cases (19 
cases of AML1/ETO and 12 cases of CBF/MYH11) without CBF cytogenetic abnormalities, 
increasing the overall detection rate of “t(8;21)(q22;q22)” and “inv(16)(p13q22)” from 8.1% to 
12.9% and from 6.5% to 10.3%, respectively. The authors of these studies concluded that all 
primary AML should be routinely tested for the presence of the CBF fusion genes by 
molecular screening to improve genomic stratification of AML patients in risk-related 
treatment groups (Marcucci et al., 2000). 
Although patients with CBF-AML have a relatively good prognosis, a substantial number of 
them relapse and eventually die of their disease. Because relapse after intensive treatment is 
likely to occur as the result of failure to completely eradicate the leukemic blasts, evaluation 
of MRD by a sensitive molecular technique such as PCR based techniques has been 
proposed to detect persistence of malignant clones and predict disease relapse in AML 
patients in CR. This strategy has been successful in CML (Radich et al.,1995) and acute 
promyelocytic leukemia (Grimwade et al., 2002; Wang et al., 2008), but its clinical 
applicability to other subgroups of acute leukemia remains controversial. 
RQ-PCR provides the most sensitive parameters for AML with reciprocal gene fusions 
PML/RAR, CBF–MYH11, AML1–ETO (Haferlach et al., 2007). The score of gene 
expression of the respective fusion transcripts after consolidation therapy in relation to gene 
expression at diagnosis correlates significantly with prognosis [Haferlach et al., 2007]. The 
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prognostic value of quantitative PCR in MRD diagnostics in these subgroups was 
demonstrated in several studies. Patients with an MRD level<1% after induction 
chemotherapy in relation to initial diagnosis had a relapse rate of 8% in contrast to 91% in 
the patients with MRD levels of ≥1% in the investigation on the CBF-leukemias by Krauter 
et al.,2003. Marcucci et al, 2000, were able to define a distinct transcript copy number in 
inv(16)/CBFB/ MYH11 below which relapse was unlikely and above which relapse 
occurred with high probability. A Gruppo Italiano Malattie Ematologiche Maligne dell’ 
Adulto (GIMEMA) trial showed that molecular switch from CR to PML/RAR positivity 
was followed by hematologic relapse after a median time of 3 months in 95% of all APL 
cases (Diverio et al. 1998). Data from different studies indicate that of all AML subtypes, 
quantitative PCR monitoring could be best established for the reciprocal gene fusions. 
Molecular analyses enabled 23.7% of the cases of our study to be classified in the adequate 
genetic entities of AML with different prognosis requiring different therapeutically 
approach.  
5.3 Analyses of the clinical characteristics of the patients in the era of modern 
diagnosis of AML 
5.3.1 Analyses of the EKOG performance status 
Several studies support the use of the ECOG performance status as a measure of physical 
functioning and prognosis in patients with AML (Oken et al. 1982). A retrospective study of 
data from five Southwestern Oncology Group (SWOG) trials that included 968 patients with 
AML found that the mortality rate within 30 days of initiation of induction therapy is 
dependent upon both the patient's age and ECOG performance status at diagnosis. A 
second retrospective analysis of 998 patients age 65 or greater (range 65 to 89; median 71 
years) who underwent intensive induction chemotherapy reported eight-week mortality 
rates of 23, 40, and 72 percent for patients with ECOG PS of zero to 1, 2, and 3 to 4, 
respectively. One-year overall survival rates for the same groups were 35, 25, and 7 percent, 
respectively. A third retrospective study of 2767 patients with non-APL AML from the 
Swedish acute leukemia registry also reported that older patients with an ECOG PS of zero 
to 1 had 30 day death rates after intensive chemotherapy of less than 15 percent, while 
patients with a PS of 3 or 4 had higher early death rates regardless of patient age ranging 
from 26 to 36 percent. Seventy percent of patients up to age 80 years had a PS of zero to 2. A 
prospective trial of induction chemotherapy with cytarabine plus daunorubicin in 811 older 
adults (median age 67 years, range 60 to 83 years) with ECOG PS of zero to 2 reported a 30-
day mortality rate of 11 percent (Appelbaum et al, 2006). We used the EKOG performance 
status score in initial randomization of our AML patients for different induction and 
consolidation approaches, in order to avoid intensive induction and consolidation treatment 
for patient with EKOG performance status higher than 2. Only 8 (12.5%) patients from our 
study group have EKOG performance status higher than 2, but only 3 of those patients were 
younger than 60 years of age.  
5.3.2 Analyses of the comorbidities  
Comorbidity is an also a distinct additional clinical entity that exists or may occur during 
the clinical course of patient with a primary disease (i.e. AML).  Comorbid conditions are 
poor prognostic factors especially in older patients with AML. Patients with age-related 
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chronic cardiac, pulmonary, hepatic or renal disorders or diabetes suffer greater acute 
toxicity from chemotherapy. Older patients may also have decreased bone marrow 
regenerative capacity, even after successful leukemia cytoreduction. Inability to tolerate long 
periods of pancytopenia and malnutrition or the nephrotoxicity of drugs such as amino 
glycosides or amphotericin remains a major barrier to successful treatment (Piccirillo et 
al.2004; Sorror et al, 2005). Six 6(9,3%) patients from our study had seriouos comorbidities 
which limited the aplication of intensive chemotherapy in their treatment. Five of them were 
older than 60years. 
5.4 Approach to AML diagnostic algorithms 
Modern diagnostic approaches in the AML should be created as integral and basic parts of 
optimized treatment concepts for the benefit of the each individual patient. The ultimate test 
of any disease diagnostic algorithm approach is its usefulness in guiding the selection of 
effective treatment strategies. Algorithms that provide a basis for risk-adapted therapeutic 
choices may include immunological markers, cytogenetic factors, molecular markers as well 
as clinical parameters (e.g., age, attainment of an early or late complete remission) and 
hematological determinants (e.g., secondary AML, white blood cell count at diagnosis) 
(Haferlach et al., 2007). 
A comprehensive approach in diagnosis, classification, and treatment follow-up in patients 
with acute leukemias can, therefore, be suggested by diagnostic algorithms, which also 
show the relationship and the hierarchy between single methods. These standard guidelines 
for AML mostly result from a combination of different methods and intend to add 
prognostic information (Lowenberg 2008). 
Our diagnostic algorithm for AML (as shown in Fig. 8) starts with cytomorphology and 
cytochemistry. These methods should be performed in combination: cytomorphology and 
cytochemistry allow rapid classification of the acute leukemias and further enables the 
choice of the antibody panel for flow cytometric analyses. In case cytomorphology gives 
indices for characteristic aberrations—in the FAB subtypes M3/M3v for t(15;17)/PML/ 
RAR, in FAB M4eo for inv(16)/CBF/MYH11, or in M1/2 with the characteristic long 
Auer rods for the t(8;21)/AML1/ETO, PCR analyses for these rearrangements should be 
promptly applied. 
Especially in case of suspicion for APL due to clinical symptoms or due to the 
morphological findings, RT-PCR for PML/RARshould be initiated as soon as possible 
(Schoch et al., 2002). We think that, regardless of the morphological, cytochemical and 
immunological futures of the blast cells, RT-PCR for the fusion oncogene PML/RARare 
recommendable in all AML cases. The RT- PCR method is the most sensitive and rapid 
technique for detection of this oncogene and provides an optimal basis for MRD analyses.  
Further we suggest all AML cases which are PML/RARnegative to be tested for the 
presence of the reciprocal fusions genes that describe CBF-AML, AML1/ETO and 
CBF/MYH11.Those analyses provides the basis for sub-classification of the AML cases in 
prognostically relevant subclasses. This is the prerequisite for adequate individual clinical 
risk stratification and therapeutic decisions. 
Moreover, we correlated the obtained result for the applied multimodal diagnostic approach 
with the patient age, EKOG performance status and comorbidities, which allowed us to 
optimize the individual risk stratification for each AML patient.  
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Fig. 8. Diagnostic algorithm and algorithm for risk adapted therapy in AML patients  
6. Conclusions 
A basis for every therapeutic decision in AML cases should be provided by a multimodal 
diagnostic approach. The optimal therapeutic conditions are based on exact classification 
and prognosis of the AML subtype at diagnosis and to delineation of sensitive markers for 
MRD studies during the complete hematologic remission. MRD methods have many 
potential applications in the clinical management of patients with acute leukemia. Today, a 
multimodal diagnostic approach which combines different diagnostic techniques is needed 
to meet these requirements. The diagnostic process is becoming more demanding with 
respect to experience, time and costs due to the expansion of methods and algorithms, 
which guide the diagnostic procedure from basic to more specific methods and which 
finally lead to results that are essential for modern diagnostics and therapeutic concepts. 
There are numerous overlaps between different diagnostic methods. These can be used for 
optimal pathways in the complex diagnostic proceedings and for validation of the results of 
single methods, which can be summarized in diagnostic algorithms. Basic morphological 
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and cytochemical analyses performed in our study group established the lineage assignment 
of the blasts cells in 68 (88.3%) patients. Routine immunophenotyping improved the 
diagnosis in 12 (15.5%) more cases. Molecular analyses enabled 23.7% of the cases from our 
study to be classified in the adequate genetic entities of AML with different prognosis 
requiring different therapeutical approach. 
The applied multimodal diagnostic approach consisted of minimal number of 
cytomorphological, cytochemistry, immunological and molecular analyses enables improved 
and more precise diagnosis and clinical stratification in 38.2% acute leukemia patients from our 
study. Moreover, when we correlate those results with the results obtained from the analyses of 
the EKOG performance status and the incidence of the serious comborbidities in our study 
group, an additional 12.5% of the patients were stratified to a different risk adapted therapy. 
Our initial results are consistent with literature data and indicate that our applied 
multimodal diagnostic approach improved the diagnosis of the specific genetic entities of 
AML in which specific treatment approach is indicated and allows individual clinical 
stratification in treatment protocols of the patients.  
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